Abstract
The blood concentrations of BMY-28100 were compared by a cross-over test in 10 healthy volunteers who were given peroral administration of 250 mg of this agent in a fasting state and after a meal.
The mean blood concentration formed a peak (Tmax), demonstrating almost the same values for peak formation. Cmax for administration with fasting was approximately 1.4 times higher. The half-life (T1/2) was approximately 7.2 min shorter for administration with fasting. The areas under the simulation curves (AUC) for administration with fasting were 1.35 times larger than after a meal.
BMY-28100 appears to be a drug which is nct susceptible to the effects of a meal.
